메뉴 건너뛰기




Volumn 47, Issue 5, 2008, Pages

Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan

(65)  Umemura, Takeji a   Tanaka, Eiji a   Kiyosawa, Kendo a,c   Kumada, Hiromitsu b   Ishikawa, Tetsuya d   Otake, Takaaki e   Ishii, Kunihide f   Fukai, Kenichi g   Hiasa, Yoichi h   Onji, Morikazu h   Tanabe, Yuichi i   Fujio, Kozou j   Sakata, Tatsuro k   Tomita, Eiichi l   Hagiwara, Hideki m   Kitamoto, Mikiya n   Takahashi, Shoichi o   Oka, Yuji p   Abe, Koichi q   Oketani, Makoto r   more..


Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RITUXIMAB; SERUM ALBUMIN; VIRUS DNA;

EID: 49449086590     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/590968     Document Type: Article
Times cited : (135)

References (31)
  • 1
    • 0016434332 scopus 로고
    • Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders
    • Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68:105-12.
    • (1975) Gastroenterology , vol.68 , pp. 105-112
    • Wands, J.R.1    Chura, C.M.2    Roll, F.J.3    Maddrey, W.C.4
  • 2
    • 0016698251 scopus 로고
    • Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy
    • Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2:528-30.
    • (1975) Lancet , vol.2 , pp. 528-530
    • Galbraith, R.M.1    Eddleston, A.L.2    Williams, R.3    Zuckerman, A.J.4
  • 4
    • 0020079497 scopus 로고
    • Reactivation of chronic hepatitis B virus infection by cancer chemotherapy
    • Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96:447-9.
    • (1982) Ann Intern Med , vol.96 , pp. 447-449
    • Hoofnagle, J.H.1    Dusheiko, G.M.2    Schafer, D.F.3
  • 5
    • 0026088152 scopus 로고
    • Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study
    • Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991; 100:182-8.
    • (1991) Gastroenterology , vol.100 , pp. 182-188
    • Lok, A.S.1    Liang, R.H.2    Chiu, E.K.3    Wong, K.L.4    Chan, T.K.5    Todd, D.6
  • 6
    • 10744222282 scopus 로고    scopus 로고
    • Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
    • Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125:1742-9.
    • (2003) Gastroenterology , vol.125 , pp. 1742-1749
    • Lau, G.K.1    Yiu, H.H.2    Fong, D.Y.3
  • 7
    • 2342580717 scopus 로고    scopus 로고
    • Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy
    • Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004; 83:270-5.
    • (2004) Ann Hematol , vol.83 , pp. 270-275
    • Leaw, S.J.1    Yen, C.J.2    Huang, W.T.3    Chen, T.Y.4    Su, W.C.5    Tsao, C.J.6
  • 8
    • 1542503712 scopus 로고    scopus 로고
    • Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy
    • Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22:927-34.
    • (2004) J Clin Oncol , vol.22 , pp. 927-934
    • Yeo, W.1    Chan, P.K.2    Ho, W.M.3
  • 9
    • 12344315888 scopus 로고    scopus 로고
    • Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients
    • Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88:209-15.
    • (2004) Breast Cancer Res Treat , vol.88 , pp. 209-215
    • Yeo, W.1    Ho, W.M.2    Hui, P.3
  • 10
    • 33847701354 scopus 로고    scopus 로고
    • Chronic hepatitis B
    • Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-39.
    • (2007) Hepatology , vol.45 , pp. 507-539
    • Lok, A.S.1    McMahon, B.J.2
  • 11
    • 0026782953 scopus 로고
    • Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen
    • Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 1992; 103:1649-56.
    • (1992) Gastroenterology , vol.103 , pp. 1649-1656
    • Kuhns, M.1    McNamara, A.2    Mason, A.3    Campbell, C.4    Perrillo, R.5
  • 12
    • 0027375850 scopus 로고
    • Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B
    • Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993; 18:1313-8.
    • (1993) Hepatology , vol.18 , pp. 1313-1318
    • Fong, T.L.1    Di Bisceglie, A.M.2    Gerber, M.A.3    Waggoner, J.G.4    Hoofnagle, J.H.5
  • 13
    • 0028047191 scopus 로고
    • Hepatitis B virus persistence after recovery from acute viral hepatitis
    • Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93:230-9.
    • (1994) J Clin Invest , vol.93 , pp. 230-239
    • Michalak, T.I.1    Pasquinelli, C.2    Guilhot, S.3    Chisari, F.V.4
  • 14
    • 0345195966 scopus 로고    scopus 로고
    • Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: A retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc
    • Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66:616-9.
    • (1998) Transplantation , vol.66 , pp. 616-619
    • Dhedin, N.1    Douvin, C.2    Kuentz, M.3
  • 15
    • 0036669971 scopus 로고    scopus 로고
    • Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease
    • Seth P, Alrajhi AA, Kagevi I, et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant 2002; 30:189-94.
    • (2002) Bone Marrow Transplant , vol.30 , pp. 189-194
    • Seth, P.1    Alrajhi, A.A.2    Kagevi, I.3
  • 16
    • 27444444509 scopus 로고    scopus 로고
    • Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: Case report and review of the literature
    • Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005; 41:1277-82.
    • (2005) Clin Infect Dis , vol.41 , pp. 1277-1282
    • Kempinska, A.1    Kwak, E.J.2    Angel, J.B.3
  • 17
    • 0035804282 scopus 로고    scopus 로고
    • Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab
    • Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344:68-9.
    • (2001) N Engl J Med , vol.344 , pp. 68-69
    • Dervite, I.1    Hober, D.2    Morel, P.3
  • 18
    • 0042941863 scopus 로고    scopus 로고
    • Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy
    • Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102:1930.
    • (2003) Blood , vol.102 , pp. 1930
    • Westhoff, T.H.1    Jochimsen, F.2    Schmittel, A.3
  • 19
    • 24044431565 scopus 로고    scopus 로고
    • HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
    • Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11:189-91.
    • (2005) J Infect Chemother , vol.11 , pp. 189-191
    • Sarrecchia, C.1    Cappelli, A.2    Aiello, P.3
  • 20
    • 22144436318 scopus 로고    scopus 로고
    • Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations
    • Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46:1085-9.
    • (2005) Leuk Lymphoma , vol.46 , pp. 1085-1089
    • Law, J.K.1    Ho, J.K.2    Hoskins, P.J.3    Erb, S.R.4    Steinbrecher, U.P.5    Yoshida, E.M.6
  • 21
    • 33745838900 scopus 로고    scopus 로고
    • Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab
    • Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45:721-4.
    • (2006) Intern Med , vol.45 , pp. 721-724
    • Sera, T.1    Hiasa, Y.2    Michitaka, K.3
  • 22
    • 33746335161 scopus 로고    scopus 로고
    • Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region
    • Kitano K, Kobayashi H, Hanamura M, et al. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur J Haematol 2006; 77:255-8.
    • (2006) Eur J Haematol , vol.77 , pp. 255-258
    • Kitano, K.1    Kobayashi, H.2    Hanamura, M.3
  • 23
    • 33745753570 scopus 로고    scopus 로고
    • Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy
    • Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131:59-68.
    • (2006) Gastroenterology , vol.131 , pp. 59-68
    • Hui, C.K.1    Cheung, W.W.2    Zhang, H.Y.3
  • 24
    • 0028337236 scopus 로고
    • Transmission of hepatitis C in an isolated area in Japan: Community-acquired infection. The South Kiso Hepatitis Study Group
    • Kiyosawa K, Tanaka E, Sodeyama T, et al. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. Gastroenterology 1994; 106:1596-602.
    • (1994) Gastroenterology , vol.106 , pp. 1596-1602
    • Kiyosawa, K.1    Tanaka, E.2    Sodeyama, T.3
  • 25
    • 33746349885 scopus 로고    scopus 로고
    • Fatal HBV reactivation in a subject with anti-HBs and anti-HBc
    • Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 2006; 45:747-8.
    • (2006) Intern Med , vol.45 , pp. 747-748
    • Umemura, T.1    Kiyosawa, K.2
  • 26
    • 10744231622 scopus 로고    scopus 로고
    • Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated apalstic anemia, or acute and chronic non-A-E hepatitis
    • Umemura T, Tanaka E, Ostapowicz G, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated apalstic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis 2003; 188:1545-52.
    • (2003) J Infect Dis , vol.188 , pp. 1545-1552
    • Umemura, T.1    Tanaka, E.2    Ostapowicz, G.3
  • 27
    • 33750356541 scopus 로고    scopus 로고
    • Classification of hepatitis B virus genotypes by the PCR-invader method with genotype-specific probes
    • Tadokoro K, Kobayashi M, Yamaguchi T, et al. Classification of hepatitis B virus genotypes by the PCR-invader method with genotype-specific probes. J Virol Methods 2006; 138:30-9.
    • (2006) J Virol Methods , vol.138 , pp. 30-39
    • Tadokoro, K.1    Kobayashi, M.2    Yamaguchi, T.3
  • 28
    • 33746339209 scopus 로고    scopus 로고
    • A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update
    • Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4:936-62.
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 936-962
    • Keeffe, E.B.1    Dieterich, D.T.2    Han, S.H.3
  • 29
    • 33751214224 scopus 로고    scopus 로고
    • Liu CJ, Kao JH, Chen DS. Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. Gastroenterology 2006; 131:1656 (author reply: Gastroenterology 2006; 131:1657).
    • Liu CJ, Kao JH, Chen DS. Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. Gastroenterology 2006; 131:1656 (author reply: Gastroenterology 2006; 131:1657).
  • 30
    • 33747076653 scopus 로고    scopus 로고
    • Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection
    • Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44:326-34.
    • (2006) Hepatology , vol.44 , pp. 326-334
    • Ozasa, A.1    Tanaka, Y.2    Orito, E.3
  • 31
    • 0035196637 scopus 로고    scopus 로고
    • A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group
    • Orito E, Mizokami M, Sakugawa H, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33:218-23.
    • (2001) Hepatology , vol.33 , pp. 218-223
    • Orito, E.1    Mizokami, M.2    Sakugawa, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.